Trial ChiCTR2100051391
Publication Xia N, Research Square, 2023
Primary outcome on the report: Serious adverse events (SAE), medically attended adverse events (MAAE) and adverse events of special interest (AESI) from day 0 (after the first dose) through 12 months after the final dose; solicited adverse events (AE) for 7 days after each dose; and unsolicited adverse events for 30 days after each dose; Symptomatic COVID-19 confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test occurring at least 14 days after the second dose in the per-protocol population (participants who were followed-up for at least two weeks after the second dose and had no major protocol deviatiations)

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.